Kronos Bio, Inc. (KRON) has been on a downward spiral lately with significant selling pressure. After declining 5.6% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether ...

Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.28%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.43, delivering a surprise of 15.69%.Over the last four quarters, the company has surpas ...

Kronos Bio Reports First-Quarter 2024 Financial Results — $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 — — KB-9558 remains on track with IND-enabling studies expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 — SAN MATEO, Calif., and CAMBRIDGE, Mass., May 9, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission file number: 001-39592 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1895605 (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission file number: 001-39592 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1895605 (State or other jur ...

Exhibit 99.1 Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 $175.0 million in cash, cash equivalents and investme ...

临床试验 - 公司正在开展两项临床试验,分别为针对MYC-扩增和其他转录依赖性实体瘤的CDK9抑制剂KB-0742的Phase 1/2临床试验,以及针对复发或难治性FLT3突变急性髓系白血病的SYK抑制剂lanraplenib的Phase 1b/2临床试验[61] 合作协议 - 公司与Genentech签订了合作协议,双方将在两个肿瘤学发现研究项目上合作,聚焦于Genentech选定的转录因子靶点,利用公司的专有药物发现平台进行初步发现和研究工作[63] - 公司与Tempus签订了为期4年的研发服务协议,Tempus将为公司提供分析服务、数据许可和有机体服务,以推进KB-0742和lanraplenib的开发[64] 重组计划 - 公司为优化资源配置和控制成本,宣布了公司重组计划,包括裁员19%,预计将延长公司的现金储备至2026年[62] 资产收购 - 公司在2020年从Gilead收购了lanraplenib和entospletinib相关的资产,需要根据未来的监管和销售里程碑支付高达51.3百万美元和115.0百万美元的里程碑付款[65,66] 收入来源 - 公司目前的收入来自于与Genentech的合作协议,包括收到的2000万美元预付款,以及未来可能获得的里程碑付款[67] - 公司在2023年9月30日的三个月内实现收入917,000美元,较上年同期增加917,000美元[76] - 公司在2023年9月30日的九个月内实现收入400.2万美元,较上年同期增加400.2万美元,主要来自与Genentech的合作协议[78] 费用情况 - 研发费用为2534.4万美元,较上年同期增加194.1万美元,主要由于咨询和外部服务费用增加,与KB-0742临床试验入组和启动相关[76] - 一般及行政费用为939.8万美元,较上年同期减少73.7万美元,主要由于股份支付费用和专业服务费用减少[76] - 研发费用为6767.5万美元,较上年同期减少287.2万美元,主要由于咨询和外部服务费用以及股份支付费用和人员成本的减少[78] - 一般及行政费用为3081.3万美元,较上年同期减少207.3万美元,主要由于专业服务费用和股份支付费用的减少[78] 现金流和融资 - 公司在2023年9月30日的现金、现金等价物和投资总额为1.984亿美元,预计可为公司的计划运营费用和资本支出提供资金支持至2026年[80] - 公司主要通过股权或债务融资以及合作协议来满足现金需求,如果无法及时筹集资金,可能需要推迟、减少或终止计划活动以降低成本[81] - 公司在9个月内从发行普通股和行使股票期权中获得了40万美元的净现金[86] 会计政策 - 公司采用了ASC 606收入确认准则,根据合同识别履约义务并分配交易价格[87] - 公司需要估计研发费用和股份支付费用,并定期评估和调整[88][89] - 公司采用了黑-斯科尔斯期权定价模型来估计股票期权的公允价值[91][92][93] - 公司的现金等价物和投资主要为货币市场基金和可供出售证券,利率变动对公允价值影响不大[94] - 公司部分合同以外币计价,但外汇交易损益目前对财务影响不大[95]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission file number: 001-39592 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1895605 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to _______ Commission file number: 001-39592 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1895605 (State or othe ...

Corporate Overview March 2023 Forward-Looking Statements This presentation includes certain projections and forward-looking statements as of the date of this presentation provided by Kronos Bio, Inc. (the “Company”). The information in this presentation is current only as of its date and may have changed since that date. These projections and forward- looking statement include, but are not limited to, those regarding the Company’s product development plans and timelines, the potential benefits of the Compan ...